The Effect Of PF-03654764 +/- Allegra On Symptoms Of Allergic Rhinitis

Pfizer logo

Pfizer

Status and phase

Completed
Phase 2

Conditions

Allergic Rhinitis

Treatments

Drug: Allegra
Drug: Placebo
Drug: PF-03654764
Drug: Allegra-D

Study type

Interventional

Funder types

Industry

Identifiers

NCT01033396
B0711005

Details and patient eligibility

About

PF-03654764 should reduce the symptoms of allergic rhinitis. In this study patients will be exposed to pollen and their symptoms observed.

Enrollment

64 patients

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or female subjects 18-60 years allergic to ragweed pollen.
  • Subjects with appropriate symptom scores following exposure to ragweed in the environmental exposure unit.

Exclusion criteria

  • Subjects with significant diseases other than allergic rhinitis that may interfere with the safety or efficacy of PF-03654764.
  • Subjects with significant symptoms of allergic rhinitis within the 2 weeks prior to screening.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

64 participants in 4 patient groups, including a placebo group

PF-03654764 + Allegra
Experimental group
Treatment:
Drug: PF-03654764
Drug: Allegra
PF-03654764
Experimental group
Treatment:
Drug: PF-03654764
Allegra-D
Active Comparator group
Treatment:
Drug: Allegra-D
Placebo
Placebo Comparator group
Treatment:
Drug: Placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems